Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;46(1):4-13.
doi: 10.1159/000495771. Epub 2019 Feb 5.

CAR-Expressing Natural Killer Cells for Cancer Retargeting

Affiliations
Free PMC article
Review

CAR-Expressing Natural Killer Cells for Cancer Retargeting

Stephan Kloess et al. Transfus Med Hemother. .
Free PMC article

Abstract

Since the approval in 2017 and the outstanding success of Kymriah® and Yescarta®, the number of clinical trials investigating the safety and efficacy of chimeric antigen receptor-modified autologous T cells has been constantly rising. Currently, more than 200 clinical trials are listed on clinicaltrial.gov. In contrast to CAR-T cells, natural killer (NK) cells can be used from allogeneic donors as an "off the shelf product" and provide alternative candidates for cancer retargeting. This review summarises preclinical results of CAR-engineered NK cells using both primary human NK cells and the cell line NK-92, and provides an overview about the first clinical CAR-NK cell studies targeting haematological malignancies and solid tumours, respectively.

Keywords: CAR-NK cell; Chimeric antigen receptor; Haematological malignancies; NK-92; Natural killer cells; Solid tumour.

Figures

Fig. 1
Fig. 1
GMP-compliant manufacturing of CAR-T cells.

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles
Feedback